Skip to main content
Article
Adjuvant High-Dose Bolus Interleukin-2 for Patients With High-Risk Renal Cell Carcinoma: A Cytokine Working Group Randomized Trial
Journal of Clinical Oncology (2003)
  • Joseph I. Clark, Loyola University Chicago
  • Michael B. Atkins, Beth Israel Deaconess Medical Center
  • Walter J. Urba, Providence Portland Medical Center
  • Steven Creech, Loyola University Medical Center
  • Robert A. Figlin, University of California, Los Angeles
  • Janice P. Dutcher, New York Medical College
  • Larry Flaherty, Vanderbilt University
  • Jeffrey A. Sosman, University of Illinois at Chicago
  • Theodore F. Logan, Indiana University Bloomington
  • Richard White, Harvard University
  • Geoffrey R. Weiss, University of Texas Health Science Center at San Antonio
  • Bruce G. Redman, University of Michigan
  • Christopher P.G. Tretter, Loyola University Chicago
  • David McDermott, Beth Israel Deaconess Medical Center
  • John W. Smith, Loyola University Chicago
  • Michael S. Gordon, State University of New York Upstate Medical University
  • Kim A. Margolin, City of Hope National Medical Center
Publication Date
August 15, 2003
DOI
10.1200/JCO.2003.02.014
Citation Information
Joseph I. Clark, Michael B. Atkins, Walter J. Urba, Steven Creech, et al.. "Adjuvant High-Dose Bolus Interleukin-2 for Patients With High-Risk Renal Cell Carcinoma: A Cytokine Working Group Randomized Trial" Journal of Clinical Oncology Vol. 21 Iss. 16 (2003) p. 3133 - 3140
Available at: http://works.bepress.com/walter-urba/213/